AbbVie Inc (NYSE:ABBV) EVP Henry O. Gosebruch sold 42,450 shares of the stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $90.10, for a total value of $3,824,745.00. Following the transaction, the executive vice president now owns 30,350 shares in the company, valued at approximately $2,734,535. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NYSE:ABBV opened at $94.27 on Friday. The company has a market cap of $135.24 billion, a P/E ratio of 16.83, a P/E/G ratio of 0.84 and a beta of 1.62. AbbVie Inc has a 1 year low of $77.50 and a 1 year high of $125.86. The company has a debt-to-equity ratio of 8.70, a quick ratio of 1.08 and a current ratio of 1.20.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, November 2nd. The company reported $2.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.01 by $0.13. The business had revenue of $8.24 billion for the quarter, compared to the consensus estimate of $8.23 billion. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The firm’s quarterly revenue was up 17.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.41 earnings per share. On average, analysts anticipate that AbbVie Inc will post 7.93 EPS for the current fiscal year.
A number of equities analysts have recently weighed in on the company. ValuEngine upgraded AbbVie from a “sell” rating to a “hold” rating in a research note on Monday, November 12th. Argus lowered their target price on AbbVie from $130.00 to $115.00 and set a “buy” rating on the stock in a research note on Tuesday, November 6th. BMO Capital Markets lowered their target price on AbbVie from $78.00 to $71.00 and set an “underperform” rating on the stock in a research note on Monday, November 5th. Barclays reiterated a “hold” rating and set a $90.00 target price on shares of AbbVie in a research note on Sunday, November 4th. Finally, Credit Suisse Group set a $85.00 target price on AbbVie and gave the stock a “hold” rating in a research note on Friday, November 2nd. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. AbbVie presently has a consensus rating of “Hold” and a consensus price target of $103.68.
Large investors have recently modified their holdings of the stock. Financial Gravity Wealth Inc. acquired a new stake in shares of AbbVie in the 1st quarter valued at $396,000. Rainier Group Investment Advisory LLC acquired a new stake in shares of AbbVie in the 1st quarter valued at $161,000. Amalgamated Bank boosted its holdings in shares of AbbVie by 10.9% in the 1st quarter. Amalgamated Bank now owns 233,519 shares of the company’s stock valued at $22,103,000 after purchasing an additional 22,873 shares in the last quarter. Quad Cities Investment Group LLC acquired a new stake in shares of AbbVie in the 1st quarter valued at $359,000. Finally, Vestpro Financial Partners Inc. dba CPF Texas boosted its holdings in shares of AbbVie by 222.5% in the 1st quarter. Vestpro Financial Partners Inc. dba CPF Texas now owns 23,567 shares of the company’s stock valued at $2,231,000 after purchasing an additional 16,259 shares in the last quarter. 69.26% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “AbbVie Inc (ABBV) EVP Henry O. Gosebruch Sells 42,450 Shares” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2018/12/02/abbvie-inc-abbv-evp-henry-o-gosebruch-sells-42450-shares.html.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.
Featured Story: What are defining characteristics of a correction?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.